-
Tacalcitol Induces NGF in Human Keratinocytes
2026-09-21
The reference study showed that tacalcitol induces dose-dependent nerve growth factor production and NGF mRNA expression in human epidermal K-TL-1 keratinocytes. Its time-course, dose-response, ELISA, and RT-PCR findings provide a mechanistic basis for studying vitamin D receptor signaling in skin biology, while also defining important limits for translation to peripheral neuropathy models.
-
EZ Cap EGFP mRNA 5-moUTP for Reporter Assays
2026-09-21
EZ Cap EGFP mRNA 5-moUTP provides a defined fluorescent reporter for comparing delivery systems, translation efficiency, and intracellular stability. Its Cap1 architecture, 5-methoxyuridine modification, and approximately 100-nucleotide poly(A) tail make it especially useful when strong signal must be separated from carrier performance.
-
Mitochondrial Calcium Signaling Represses Ferroptosis
2026-09-20
The reference study identifies mitochondrial calcium uptake through MCU as a metabolic regulator of ferroptosis, linking PDH-derived acetyl-CoA to GPX4 acetylation at lysine 90. Its genetic, rescue, structural, and tumor-model experiments suggest that mitochondrial calcium signaling can preserve GPX4 activity and support cancer-cell survival, while also defining important limits for translation.
-
Caffeine Workflows for Cancer and Metabolic Research
2026-09-19
Build reproducible Caffeine assays for cancer cell line inhibition, metabolic phenotyping, and neurobiology while keeping dose, vehicle, and mechanism controls aligned. The workflow also distinguishes adenosine-receptor biology from the ALDH2 activator strategy reported for myocardial ischemia research.
-
Cyclophilin A and Cyclosporin Immunosuppression
2026-09-18
Colgan et al. used genetic deletion and immune-reconstitution models to show that Cyclophilin A is the principal mediator of Cyclosporin-mediated immunosuppression in mice. Their results connect drug-dependent calcineurin inhibition directly to a defined intracellular ligand and provide a framework for interpreting T-cell assays and transplantation models.
-
Resveratrol, Smad Signaling, and GBM Invasion
2026-09-18
The reference study shows that resveratrol suppresses TGF-β1-induced epithelial–mesenchymal transition, migration, invasion, and stem-like behavior in glioblastoma models through Smad-dependent signaling. Its combination of molecular, functional, stemness, and xenograft assays provides a useful framework for studying TGF-β signaling pathway modulation in GBM.
-
Hoechst 33342 for TNT Transport Assays
2026-09-17
Hoechst 33342 adds a live-cell nuclear reference to tunneling nanotube transport experiments, supporting cell segmentation, chromatin visualization, and morphology scoring alongside lipid-droplet tracking. This guide connects practical staining parameters with the force-resolved multimotor workflow reported in the reference study.
-
Z-VAD-FMK in Apoptosis and Redox Barrier Studies
2026-09-17
Use Z-VAD-FMK to determine whether oxidative or inflammatory injury is genuinely caspase dependent rather than simply measuring cell loss. This workflow connects apoptosis inhibition with epithelial barrier, immune-cell, and redox assays while emphasizing controls, dosing discipline, and interpretation limits.
-
Axitinib (AG 013736) Assay Workflow Guide
2026-09-16
A practical guide to using Axitinib (AG 013736) in VEGFR-focused angiogenesis inhibition assays, cancer cell response studies, and xenograft-aligned workflows. It combines concentration planning, dual viability-and-death readouts, and troubleshooting strategies to distinguish pathway suppression from nonspecific cytotoxicity.
-
Carboplatin Workflows for Resistance Research
2026-09-16
Build reproducible Carboplatin cytotoxicity assays while distinguishing DNA damage from cancer stem-cell-mediated resistance. This workflow connects concentration-response testing with the IGF2BP3–FZD1/7 mechanism reported in triple-negative breast cancer.
-
AG-221 (Enasidenib): Reading 2-HG Biology
2026-09-15
AG-221 (Enasidenib) is more than an IDH2 inhibitor: it is a mechanistic probe for connecting 2-hydroxyglutarate reduction with leukemia-cell state and metabolic dependency. This guide develops an assay-centered framework informed by recent CD44 research without duplicating conventional resistance or workflow summaries.
-
Axitinib: From VEGFR Potency to Assay Meaning
2026-09-15
Axitinib (AG 013736) is examined through a dual-metric framework that separates growth inhibition from cell death. This article translates VEGF pathway pharmacology into more rigorous angiogenesis assays, cancer biology research, and xenograft interpretation.
-
BCL-XL inhibitor A-1155463: From Mechanism to Translation
2026-09-14
A mechanism-first perspective on how A-1155463 can help translational researchers interrogate apoptotic dependence, drug resistance, and therapeutic vulnerability across glioblastoma, solid tumors, and hematological malignancies. The article connects published glioblastoma biology with practical experimental design while clearly distinguishing tool-compound evidence from clinical readiness.
-
CPI-613: Mitochondrial Assay Workflows
2026-09-14
CPI-613 enables a practical bridge between mitochondrial metabolism, apoptosis, and chemotherapy-sensitization assays. This workflow-oriented guide shows how to test 6,8-bis(benzylsulfanyl)octanoic acid in tumor cells and mechanism-focused cholangiocarcinoma models while controlling solubility, vehicle, and endpoint variability.
-
Sunitinib: Multi-Targeted RTK Inhibitor
2026-09-13
Sunitinib is an orally bioavailable, multi-targeted receptor tyrosine kinase inhibitor with nanomolar activity against VEGFR, PDGFR, KIT, and RET. Research applications include tumor angiogenesis, apoptosis induction in renal cell carcinoma, cell cycle arrest at G0/G1 phase, and nasopharyngeal carcinoma research.